Wedbush reissued their buy rating on shares of Obseva (NASDAQ:OBSV) in a research note issued to investors on Tuesday, AnalystRatings.com reports. They currently have a $36.00 price target on the stock.
Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Obseva from a strong sell rating to a sell rating in a research report on Wednesday, October 30th. Zacks Investment Research upgraded shares of Obseva from a sell rating to a hold rating in a research report on Saturday, November 9th. Credit Suisse Group downgraded shares of Obseva from an outperform rating to a neutral rating and reduced their price target for the stock from $16.00 to $4.00 in a research report on Friday, November 8th. Royal Bank of Canada upped their price target on shares of Obseva from $18.00 to $19.00 and gave the stock an outperform rating in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a buy rating and set a $40.00 price target on shares of Obseva in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $24.75.
Shares of NASDAQ:OBSV traded down $0.36 on Tuesday, hitting $3.92. The stock had a trading volume of 982,326 shares, compared to its average volume of 752,357. Obseva has a twelve month low of $2.37 and a twelve month high of $14.59. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.65 and a current ratio of 3.65. The firm’s 50 day moving average price is $3.71 and its 200-day moving average price is $6.88. The company has a market capitalization of $194.65 million, a price-to-earnings ratio of -1.58 and a beta of 0.50.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley lifted its position in Obseva by 358.6% during the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after buying an additional 2,424 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Obseva by 263.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after purchasing an additional 2,372 shares during the last quarter. Wedbush Securities Inc. raised its holdings in Obseva by 54.2% during the 3rd quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock worth $334,000 after purchasing an additional 14,100 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Obseva by 96.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,923 shares of the company’s stock worth $366,000 after purchasing an additional 47,012 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Obseva by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after purchasing an additional 5,600 shares during the last quarter. Institutional investors and hedge funds own 63.53% of the company’s stock.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.